Surrozen, Inc.
A clinical-stage biotech that turns the body's own repair signals into medicines, Surrozen builds antibody drugs that mimic Wnt proteins — the natural molecules that tell tissue to regenerate. Founded in 2015 by Stanford and other scientists, its lead work targets sight-threatening eye diseases like wet age-related macular degeneration. The name blends "surrogate" and "zen": the engineered antibodies act as stand-ins for the body's repair messengers, long considered impossible to turn into drugs.
Warrant expiring August 1, 2031
Bought 65.6K
Bought 417.2K
Bought 351.6K
Bought 199.1K
Granted 10.2K · Sold 2.7K
Granted 12.5K · Sold 3.6K
Granted 15.7K · Sold 4.5K
Granted 607
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Svennilson Peter +6 co-filers10% owner · 12 transactions | — | 2.26M | — | 65.6K | — |
| Kutzkey TimDirector, 10% owner · 18 transactions | +22.6% | 2.26M | — | 417.2K | — |
| Column Group III GP, LP +5 co-filers10% owner · 6 transactions | +19.1% | 2.20M | — | 351.6K | — |
| TCG Crossover Fund II, L.P. +3 co-filers10% owner · 20 transactions | — | 1.47M | — | 199.1K | — |
| Li YangExec. Vice President, Research · 7 transactions | — | 20.3K | 10.2K | — | 2.7K |
| Williams Charles OChief Operating Officer · 6 transactions | +94.4% | 18.2K | 12.5K | — | 3.6K |
| Parker Craig CChief Executive Officer, Director · 4 transactions | +158.8% | 18.2K | 15.7K | — | 4.5K |
| Maleki Andrew PedrumChief Financial Officer · 1 transaction | — | 607 | 607 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +1.02M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.